Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer's disease: A 4-year follow-up study

Journal of Neural Transmission

Volumn 121, Issue 2, 2014, Pages 193-200

  Gattaz, Wagner F ^a   Talib, Leda L ^a   Schaeffer, Evelin L ^a   Diniz, Breno S ^a   Forlenza, Orestes V ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer's disease; Mild cognitive impairment; Phospholipase A2

Indexed keywords

BIOLOGICAL MARKER; CYTOSOLIC PHOSPHOLIPASE A2; DONEPEZIL; GALANTAMINE; INTRACELLULAR CALCIUM INDEPENDENT PHOSPHOLIPASE A2; PHOSPHOLIPASE A2; RIVASTIGMINE; SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOCYTE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DISEASE PROGRESSION; FEMALE; GROUP VI PHOSPHOLIPASES A2; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 84893741320     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1088-8     Document Type: Article

References (59)

1. Arioka M, Cheon SH, Ikeno Y, Nakashima S, Kitamoto K (2005) A novel neurotrophic role of secretory phospholipases A2 for cerebellar granule neurons. FEBS Lett 579:2693-2701
2. Bakken AM, Staeffler A, Jørgensen HA, Holmsen H (2006) Glycerophospholipid molecular species in platelets and brain tissues - are platelets a good model for neurons? Platelets 17(7):484-492
3. Bianchi M, Moser C, Lazzarini C, Vecchiato E, Crespi F (2002) Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes. Exp Brain Res 143(2):191-197
4. Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O (2010) Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging 31(11):1877-1884
5. Burke JE, Dennis EA (2009) Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 50 (SUPPL. S2):37-42
6. 2+-dependent phospholipase A2 activity is increased in Alzheimer disease. Clin Chem 55(12):2171-2179
7. Cho HW, Kim JH, Choi S, Kim HJ (2006) Phospholipase A2 is involved in muscarinic receptor-mediated sAPPα release independently of cyclooxygenase or lypoxygenase activity in SHSY5Y cells. Neurosci Lett 397:214-218
8. Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ (2002) Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 70:462-473
9. Dennis EA (1994) Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 269(18):13057-13060
10. De-Paula VJ, Schaeffer EL, Talib LL, Gattaz WF, Forlenza OV (2010) Inhibition of phospholipase A2 increases tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. Prostaglandins Leukot Essent Fatty Acids 82:57-60
11. Diniz BS, Nunes PV, Yassuda MS, Pereira FS, Flaks MK, Viola LF, Radanovic M, Abreu ID, Borelli DT, Gattaz WF, Forlenza OV (2008) Mild cognitive impairment: cognitive screening or neuropsychological assessment? Rev Bras Psiquiatr 30:316-321
12. Diniz BS, Teixeira AL, Ojopi EB, Talib LL, Mendonça VA, Gattaz WF, Forlenza OV (2010) Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis 22(4):1305-1311
13. Emmerling MR, Moore CJ, Doyle PD, Carroll RT, Davis RE (1993) Phospholipase A2 activation influences the processing and secretion of the amyloid precursor protein. Biochem Biophys Res Commun 197:292-297
14. Emmerling MR, Dudley DT, Dyer RD, Carroll RT, Doyle PD, Davis RE (1996) The role of arachidonic acid in the secretion of the amyloid precursor protein (APP). Ann N Y Acad Sci 777:310-315
15. Farooqui AA, Horrocks LA (2004) Brain phospholipases A2: a perspective on the history. Prostaglandins, Leucotrienes and Essential Fatty acids 71:161-169
16. Folstein MF, Folstein SE, Mchugh PR (1975) Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
17. Fonteh AN, Chiang J, Cipolla M, Hale J, Diallo F, Chirino A, Arakaki X, Harrington MG (2013) Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease. J Lipid Res. Jul 18 [Epub ahead of print]
18. Forlenza OV, Schaeffer EL, Gattaz WF (2002) Phospholipase A2 activity in rat embryonic brain and in primary cultures of cortical neurons. J Neural Transm 109(5-6):623-631
19. Forlenza OV, Wacker P, Nunes PV, Yacubian J, Castro CC, Otaduy MC, Gattaz WF (2005) Reduced phospholipid breakdown in Alzheimer's brains: a 31P spectroscopy study. Psychopharmacology 180(2):359-365
20. Forlenza OV, Mendes CT, Marie SK, Gattaz WF (2007a) Inhibition of phospholipase A2 reduces neurite outgrowth and neuronal viability. Prostaglandins Leukot Essent Fatty Acids 76:47-55
21. Forlenza OV, Schaeffer EL, Gattaz WF (2007b) The role of phospholipase A2 in neuronal homeostasis and memory formation: implications for the pathogenesis of Alzheimer's disease. J Neural Transm 114(2):231-238
22. Forlenza OV, Diniz BS, Talib LL, Mendonça VA, Ojopi EB, Gattaz WF, Teixeira AL (2009) Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 28(6):507-512
23. Forlenza OV, Diniz BS, Talib LL, Radanovic M, Yassuda MS, Ojopi EB, Gattaz WF (2010) Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment. Rev Bras Psiquiatr 32(3):216-222
24. Gattaz WF, Maras A, Cairns NJ, Levy R, Förstl H (1995) Decreased phospholipase A2 activity in Alzheimer brains. Biol Psychiatry 37:13-17
25. Gattaz WF, Cairns NJ, Levy R, Förstl H, Braus DF, Maras A (1996) Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 246(3):129-131
26. Gattaz WF, Forlenza OV, Talib LL, Barbosa NR, Bottino CM (2004) Platelet phospholipase A2 activity in Alzheimer's disease and mild cognitive impairment. Journal of Neural Transmission 111:591-601
27. Heneka MT, O'Banion MK, Terwel D, Kummer MP (2010) Neuroinflammatory processes in Alzheimer's disease. J. Neural Transm 117(8):919-947
28. Ikeno Y, Konno N, Cheon SH, Bolchi A, Ottonello S, Kitamoto K et al (2005) Secretory phospholipases A2 induce neurite outgrowth in PC12 cells through lysophosphatidylcholine generation and activation of G2A receptor. J Biol Chem 280:28044-28052
29. Krzystanek E, Krzystanek M, Opala G, Trzeciak HI, Siuda J, Małecki A (2007) Platelet phospholipase A2 activity in patients with Alzheimer's disease, vascular dementia and ischemic stroke. J Neural Transm 114(8):1033-1039
30. Lambeau G, Gelb MH (2008) Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 77:495-520
31. Masuda S, Murakami M, Takanezawa Y, Aoki J, Arai H, Ishikawa Y et al (2005) Neuronal expression and neuritogenic action of group X secreted phospholipase A2. J Biol Chem 80:23203-23214
32. Masuda S, Yamamoto K, Hirabayashi T, Ishikawa Y, Ishii T, Kudo I et al (2008) Human group III secreted phospholipase A2 promotes neuronal outgrowth and survival. Biochem J 409:429-438
33. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human Services task force on Alzheimer's disease. Neurology 34(7):939-944
34. Moses GS, Jensen MD, Lue LF, Walker DG, Sun AY, Simonyi A et al (2006) Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease. J Neuroinflammation 3:28
35. Nitsch RM, Deng A, Wurtman RJ, Growdon JH (1997) Metabotropic glutamate receptor subtype mGluR1α stimulates the secretion of the amyloid β-protein precursor ectodomain. J Neurochem 69:704-712
36. Nordberg A (2006) Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 20(2SUPPL. 1):S12-8. Review
37. Nunes PV, Diniz BS, Radanovic M, Abreu ID, Borelli DT, Yassuda MS, Forlenza OV (2008) CAMCOG as a screening tool for diagnosis of mild cognitive impairment and dementia in a Brazilian clinical sample of moderate to high education. Int J Geriatr Psychiatry 23:1127-1133
38. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild Cognitive Impairment: clinical characterization and outcome. Arch Neurol 56:303-308
39. Pettegrew JW, Moossy J, Withers G, McKeag D, Panchalingam K (1988) 31P nuclear magnetic resonance study of the brain in Alzheimer's disease. J Neuropathol Exp Neurol 47:235-248
40. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R (1986) CAMDEX: a standardized Instrument for the diagnosis of mental disorders in the elderly with special reference to early detection of dementia. Br J Psychiatry 149:698-709
41. Schaeffer EL, Gattaz WF (2005) Inhibition of calcium-independent phospholipase A2 activity in rat hippocampus impairs acquisition of short- and long-term memory. Psychopharmacology 181:392-400
42. Schaeffer EL, Gattaz WF (2007) Requirement of hippocampal phospholipase A2 activity for long-term memory retrieval in rats. J Neural Transm 114:379-385
43. Schaeffer EL, Gattaz WF (2008) Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology 198(1):1-27
44. Schaeffer EL, Forlenza OV, Gattaz WF (2009a) Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology 202(1-3):37-51
45. Schaeffer EL, Zorron PuL, Gagliotti DA, Gattaz WF (2009b) Conditioning training and retrieval increase phospholipase A(2) activity in the cerebral cortex of rats. J Neural Transm 116:41-50
46. Schaeffer EL, da Silva ER, Novaes Bde A, Skaf HD, Gattaz WF (2010) Differential roles of phospholipases A2 in neuronal death and neurogenesis: implications for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 34(8):1381-1389
47. Schaeffer EL, De-Paula VJ, da Silva ER, de A Novaes B, Skaf HD, Forlenza OV, Gattaz WF (2011a) Inhibition of phospholipase A(2) in rat brain decreases the levels of total Tau protein. J Neural Transm 118(9):1273-1279
48. Schaeffer EL, Skaf HD, Novaes Bde A, da Silva ER, Martins BA, Joaquim HD, Gattaz WF (2011b) Inhibition of phospholipase A2 in rat brain modifies different membrane fluidity parameters in opposite ways. Prog Neuropsychopharmacol Biol Psychiatry 35(7):1612-1617
49. Schaeffer EL, Gattaz WF, Eckert GP (2012) Alterations of brain membranes in schizophrenia: impact of phospholipase A(2). Curr Top Med Chem 12(21):2314-2323
50. Schaloske RH, Dennis EA (2006) The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 1761(11):1246-1259
51. Smalheiser NR, Dissanayake S, Kapil A (1996) Rapid regulation of neurite outgrowth and retraction by phospholipase A2-derived arachidonic acid and its metabolites. Brain Res 721:39-48
52. Stephenson DT, Lemere CA, Selkoe DJ, Clemens JA (1996) Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol Dis 3:51-63
53. Stephenson D, Rash K, Smalstig B, Roberts E, Johnstone E, Sharp J et al (1999) Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration. Glia. 27:110-128
54. Sun GY, Xu J, Jensen MD, Simonyi A (2004) Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res 45(2):205-213
55. Sun GY, Shelat PB, Jensen MB, He Y, Sun AY, Simonyi A (2010) Phospholipases A2 and inflammatory responses in the central nervous system. Neuromolecular Med 12(2):133-148
56. Talbot K, Young RA, Jolly-Tornetta C, Lee VM, Trojanowski JQ, Wolf BA (2000) A frontal variant of Alzheimer's disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex. Neurochem Int 37(1):17-31
57. Talib LL, Yassuda MS, Diniz BS, Forlenza OV, Gattaz WF (2008) Cognitive training increases platelet PLA2 activity in healthy elderly subjects. Prostaglandins Leukot Essent Fatty Acids 78:265-269
58. Talib LL, Diniz BS, Zainaghi IA, Forlenza OV, Gattaz WF (2012) A radioenzymatic assay to identify three groups of phospholipase A(2) in platelets. Prostaglandins Leukot Essent Fatty Acids 86(4-5):149-153
59. Talib LL, Valente KD, Vincentiis S, Gattaz WF. (2013) Correlation between platelet and brain PLA(2) activity. Prostaglandins Leukot Essent Fatty Acids. doi: 10.1016/j.plefa.2013.07.002. [Epub ahead of print]